Hydroxyurea-Induced miRNA Expression in Sickle Cell Disease Patients in Africa
| Autor: | Emile R. Chimusa, Gaston K. Mazandu, Gift D. Pule, Ambroise Wonkam, Khuthala Mnika, Neil A. Hanchard, Mario Jonas |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
fetal hemoglobin lcsh:QH426-470 Cell Disease hydroxyurea 03 medical and health sciences 0302 clinical medicine Mirna expression hemic and lymphatic diseases Fetal hemoglobin microRNA Genetics Medicine MYB Gene Genetics (clinical) Original Research miRNA business.industry Peripheral blood 3. Good health lcsh:Genetics 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Africa Cancer research Molecular Medicine sickle cell disease business |
| Zdroj: | Frontiers in Genetics Frontiers in Genetics, Vol 10 (2019) |
| ISSN: | 1664-8021 |
| DOI: | 10.3389/fgene.2019.00509 |
| Popis: | Hydroxyurea (HU) is clinically beneficial in sickle cell disease (SCD) through fetal hemoglobin (HbF) induction; however, the mechanism of HU is not yet fully elucidated. Selected miRNAs have been associated with HU-induced HbF production. We have investigated differential HU-induced global miRNA expression in peripheral blood of adult SCD patients in patients from Congo, living in South Africa. We found 22 of 798 miRNAs evaluated that were differentially expressed under HU treatment, with the majority (13/22) being functionally associated with HbF-regulatory genes, including BCL11A (miR-148b-3p, miR-32-5p, miR-340-5p, and miR-29c-3p), MYB (miR-105-5p), and KLF-3 (miR-106b-5), and SP1 (miR-29b-3p, miR-625-5p, miR-324-5p, miR-125a-5p, miR-99b-5p, miR-374b-5p, and miR-145-5p). The preliminary study provides potential additional miRNA candidates for therapeutic exploration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|